2025-521872-69-00招募中1 期
OMTX705-006 Phase 1b
Oncomatryx Biopharma S.L.6 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2025年9月1日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 54
- 试验地点
- 6
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Ignacio Garcia-Ribas
Scientific
Oncomatryx Biopharma S.L.
研究点 (6)
Loading locations...
相似试验
招募中
1 期
Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with pembrolizumab in patients with advanced solid tumorsSelected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).CTIS2024-514746-36-00Oncomatryx Biopharma S.L.120
招募中
2 期
Phase 1/2 study testing for the first time in humans a novel drug, STAR0602, to selectively stimulate T cells for the treatment of subjects with advanced solid tumors that cannot be removed with surgery or has spread locally or to other parts of the body.2023-505334-10-01Marengo Therapeutics Inc.46
已完成
1 期
ONO-7705 Phase I study (ONO-7705-01)jRCT2080223979ONO PHARMACEUTICAL CO.,LTD.18
进行中（未招募）
不适用
ONO-7475-03 : ONO-7475 Phase 1 StudyjRCT2051210045Ono Pharmaceutical Co.,LTD75
已完成
1 期
ONO-7475 Phase I Study (ONO-7475-02)jRCT2080224028ONO PHARMACEUTICAL CO.,LTD.84